The pharmacokinetics of ceftizoxime were studied in 20 volunteers with various degrees of renal function. Creatinine clearances ranged from zero to 157 ml/min per 1.73 M2. One gram of ceftizoxime was administered by a 30-min drip infusion, and blood and urine samples were collected for up to 48 h after drug administration. For volunteers with a creatinine clearance of .80 ml/min per 1.73 m2 (group I), the mean half-life was 1.65 h, whereas for volunteers with a creatinine clearance of <10 ml/min per 1.73 m2 (group IV), the half-life was 34.7 h. however, serum concentrations at 48 h after drug administration were still >10 jig/ ml in dialysis subjects. By using the relationship between total body clearance of ceftizoxime and creatinine clearance, a nomogram was developed to assist in the administration of ceftizoxime to patients with renal dysfunction.
The pharmacokinetics of ceftizoxime (FK-749) were studied in 20 volunteers with various degrees of renal function. Creatinine clearances ranged from zero to 157 ml/min per 1.73 M2. One gram of ceftizoxime was administered by a 30-min drip infusion, and blood and urine samples were collected for up to 48 h after drug administration. For volunteers with a creatinine clearance of .80 ml/min per 1.73 m2 (group I), the mean half-life was 1.65 h, whereas for volunteers with a creatinine clearance of <10 ml/min per 1.73 m2 (group IV), the half-life was 34.7 h.
The volume of distribution at steady state (VdrS) and the volume of distribution area (Vda) were calculated for each group and ranged from 0.377 to 0.263 and 0.421 to 0.264 liters/kg for groups I and IV, respectively. Total body clearance of ceftizoxime correlated with creatinine clearance (r = 0.953), and the mean urinary recovery of unchanged drug in normal volunteers was 72.4%. A 4-h hemodialysis procedure reduced serum ceftizoxime concentrations by approximately 52%; however, serum concentrations at 48 h after drug administration were still >10 jig/ ml in dialysis subjects. By using the relationship between total body clearance of ceftizoxime and creatinine clearance, a nomogram was developed to assist in the administration of ceftizoxime to patients with renal dysfunction.
Ceftizoxime is a new injectable semisynthetic cephalosporin with beta-lactamase stability and broad-spectrum antibacterial activity. Since ceftizoxime is primarily dependent on the kidneys for elimination, accumulation of the drug can be anticipated in subjects with decreased renal function. The purpose of this study was to investigate the pharmacokinetics of ceftizoxime in subjects with various degrees of renal function and to establish a dosage regimen for ceftizoxime based on renal function.
MATERIALS AND METHODS Antibiotic. Ceftizoxime was supplied by Smith Kline & French Laboratories, Philadelphia, Pa., as a dry, sterile powder for reconstitution and intravenous administration.
Human volunteers. Twenty adult male and female volunteers with no known allergies to penicillin or cephalosporin antibiotics were studied after written informed consent was obtained. No volunteer had taken antibiotics for at least 72 h before the time of evaluation. Persistence of long-acting antibiotics was excluded by the absence of bioactivity in the zero-time serum samples. Each subject was selected on the basis of a prestudy 24-h creatinine clearance (Ccr) and assigned to one offour study groups (group I, C(cr . 80 ml/min per 1.73 m2; group II, Cr = 50 to 79 ml/min per 1.73 m2; group III, Ccr = 10 to 49 ml/min per 1.73 M2; and group IV, Ccr < 10 ml/min per 1.73 m2). Subjects in group IV were maintained on 4 h of hemodialysis three times a week. All subjects underwent a prestudy physical examination and laboratory evaluation and had stable renal function before their inclusion in the study. Laboratory tests obtained before and after the study protocol included a complete blood count with differential, platelet count, Coombs test (direct and indirect), SMA-18, 24-h creatinine clearance, urinalysis, and serum pregnancy test.
Procedure. Each subject fasted from midnight until 2 h after drug administration. After base-line serum and urine samples were taken, each subject was placed in the supine position and given 1.0 g of ceftizoxime by drip infusion over 30 min (via IMED infusion pump; IMED, San Diego, Calif.). Ceftizoxime was reconstituted with sterile water and mixed with 50 ml of 0.9% sodium chloride. Samples of whole blood for antibiotic serum level determinations were obtained in all subjects before and at 5, 10, 20, 30, 35, 40 , and 45 min and 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 h after the start of the infusion. Subjects in group IV were scheduled for drug administration 24 h before hemodialysis and had additional serum samples collected at 2 and 4 h during hemodialysis and at 1, 2, and 3 h post-hemodialysis. The first 14 serum samples were taken from a 0.2-mlcapacity intermittent infusion set, the first 0.5 to 1.0 ml was discarded, and a 3.0-ml blood sample was collected for analysis. The remaining samples were obtained by separate venipunctures. Blood specimens were collected in sterile, nonheparinized tubes and centri-ANTIMICROB. AGENTS CHEMOTHER.
fuged, and the serum was pipetted and immediately frozen at -70°C. Urine samples were collected before drug infusion and at intervals of 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 18, 18 to 24, and 24 to 48 h thereafter. The total volume was recorded, and a 15-mi portion was frozen at -70°C. The average storage time before sample analysis was approximately 2 months (serum and urine ceftizoxime stability studies conducted in our laboratory have demonstrated no significant difference, by the Wilcoxon signed-rank test of paired differences in medians [2] , in drug activity over a 1-year period of storage at -70°C).
Assay technique. Serum and urine samples were thawed and assayed at the same time. Escherichia coli ATCC 25922 was grown overnight in brain heart infusion broth (pH 7.4) (BBL Microbiology Systems, Cockeysville, Md.). One milliliter of this overnight culture was added to 1 liter of brain heart infusion agar (pH 7.4) (BBL), and 20 ml was then poured into 100-mm2 petri plates. Each plate was refrigerated for 2 h, after which time 4-mm wells were cut and filled with 20 p1 of sample. All serum standards and patient specimens were diluted in pooled human serum (Flow Laboratories, McLean, Va.), and urine standards and patient specimens were diluted in potassium phosphate buffer (pH 6.0) (standard sensitivity ranged from 25 to 1.52 1Lg/ml for both serum and urine The pharmacokinetic parameters described for subjects in group IV were calculated by using serum samples collected during the first 24 h of the study (i.e., before the hemodialysis procedure).
Stastical analysis. Group data and pharmacokinetic parameters were evaluated by one-way analysis of variance (ANOVA) to detect differences among groups I to IV. The relationship between total body clearance of ceftizoxime and creatinine clearance was examined for correlation by the use of an orthogonal regression plot (1).
RESULTS
The intravenous administration of ceftizoxime resulted in no local pain or phlebitis in any of the study subjects. No significant systemic toxicities occurred during or after drug administration, and poststudy laboratory tests were not significantly different from prestudy tests. Table  1 (Table 2) . Subjects in group I exhibited a decline in the concentration of ceftizoxirne such that approximately 1 ,ug/ml was present at 7.5 h after drug administration. In contrast, subjects in group IV (despite a 4-h hemodialysis at 24 h postinfusion) had ceftizoxime serum concentrations greater than 10 ,Ig/ml at 47.5 h. A 4-h hemodialysis procedure resulted in serum concentrations of ceftizoxime 51.9o lower at the end of hemodialysis than concentrations at the beginning of hemodialysis. Table 3 lists the mean pharmacokinetic parameters calculated for each group. Differences among groups I to IV were significant for the zero-time intercept for the beta elimination phase (B), beta elimination rate constant, area under the serum concentration-time curve, volume of distribution at Table 4 gives the amount of ceftizoxime excreted in the urine for groups I to IV. Approximately 98% of ceftizoxime is excreted within the first 8 h after drug administration in subjects with normal renal function. It is also apparent from Table 4 that as renal function deterorates, the amount of drug excreted within the first 8 h decreases such that 81, 51, and 33% were eliminated in groups II, III, and IV, respectively. Figure 1 shows the relationship between the creatinine clearance (x axis) and the total body clearance of ceftizoxime (y axis). The data were fitted by orthogonal regression to the line y = -11.95 + 1.792x. The correlation coefficient was 0.953, and the t test of independence was highly significant (P < 0.001). 
DISCUSSION
Ceftizoxime is a broad-spectrum cephalosporin antibiotic which possesses strong antibacterial activity against many gram-negative bacteria. The microbiological characteristics of ceftizoxime suggest that it may have excellent clinical utility in the treatment of infections caused by aerobic and anaerobic gram-negative enteric bacteria; therefore, an understanding of the pharmacokinetic parameters of ceftizoxime will enable the clinician to maximize the microbiological features of the drug and minimize antibiotic complications.
In the present study, the range in the beta elimination half-lives for subjects in groups I to IV was 1.65 38, 1981 ) and comparable to the elimination half-life data report for cefazolin (4) . Coupled with the high serum concentrations which are still above the minimum inhibitory concentrations of most susceptible organisms 8 h after drug administration, it would appear that ceftizoxime dosage administration at 8 h intervals would be appropriate in subjects with normal renal function. Urinary concentrations of ceftizoxime observed in this study would suggest that the interval of drug administration could be even longer (e.g., every 12 to 24 h) in normal subjects being treated for urinary tract infections due to susceptible gram-negative organisms.
Analysis of our data shows that the total body clearance of ceftizoxime correlated best with 24-h creatinine clearance results. Such a correlation between drug clearance and creatinine clearance makes it possible to establish a nomogram for adjusting the dose (as a percent of normal) in subjects with renal insufficiency. Functionally anephric patients in our study would theoretically receive approximately 3.0% of the usual 1.0-g intravenous dose at the same interval as subjects with normal renal function. However, in a more practical sense, an alternative would be to change the interval of administration and maintain the normal milligram dose of ceftizoxime. Although not shown on the nomogram, subjects in group II would receive 100% of the normal dose every 12 h, subjects in group III, 100% of the dose every 36 to 48 h, and subjects in group IV would receive the normal dose at some time interval greater than 48 h, depending on the frequency of hemodialysis. Utilization of this nomogram for ceftizoxime administration in subjects with renal insufficiency should provide safe and effective serum concentrations.
